RegulatoryCompany release

Faeth's PIKTOR gets FDA Fast Track in endometrial cancer as Q3 loss widens to $20.4m

🇺🇸 Faeth Therapeutics, Inc. (FTH) · Tue 03 Nov 2026

The US regulator has granted Fast Track status to PIKTOR plus paclitaxel in biomarker-selected endometrial cancer, with Phase 2 PIK-201 topline data expected by the end of 2026.

Faeth Therapeutics said on 3 November 2026 that the US Food and Drug Administration has granted Fast Track designation to PIKTOR in combination with paclitaxel. The designation covers advanced or recurrent endometrial cancer in patients whose tumours carry a PAM pathway alteration.

The designation applies to patients who have already received platinum-based chemotherapy and a checkpoint inhibitor. It therefore targets a biomarker-selected population in a later-line setting.

The company announced the designation alongside its third-quarter 2026 financial results. It expects topline data from its Phase 2 PIK-201 study by the end of the year.

Faeth reported a net loss of $20.4 million for the quarter and said it held $174.8 million in cash and marketable securities. The summary available does not include comparative figures or further detail on the company's financial guidance.

For context, Fast Track is an FDA programme intended to speed the development and review of drugs for serious conditions with unmet medical need. It allows more frequent contact with the agency and, where criteria are met, rolling submission of a marketing application.

What it means for your team

  • Fast Track status gives Faeth more frequent FDA interaction and potential rolling review, but it does not signal approval or confirm efficacy.
  • The PAM pathway alteration criterion points to a biomarker-selected population, so companion diagnostic planning is likely to matter for regulatory and market-access teams.
  • Year-end topline Phase 2 PIK-201 data will be the next key readout for assessing the programme's path forward.

Company's press release (SEC filing): Faeth Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Faeth Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →